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Human leukocyte antigen (HLA)-E is a non-classical major histocompatibility complex class I (Ib) molecule,
which plays an important role in immunosuppression. In this study, we investigated the immunomodulating
effect of HLA-E in a xenogeneic system, using human placental artery-derived endothelial (hPAE) cells
expressing HLA-E in a mouse model. In vitro cell lysis analysis by primed lymphocytes in combination
with siRNA transfection showed that HLA-E is necessary for inhibition of the immune response. Similarly,
in vivo cell implantation analysis with siRNA-mediated down-regulation of HLA-E demonstrates that HLA-E
is involved in immunosuppression. As hPAE cells efﬁciently transdifferentiate into myoblasts/myocytes
in vitro, we transplanted the cells into mdx mice, a model of Duchenne muscular dystrophy. hPAE cells
conferred dystrophin to myocytes of the ‘immunocompetent’ mdx mice with extremely high efﬁciency.
These ﬁndings suggest that HLA-E-expressing cells with a myogenic potential represent a promising
source for cell-based therapy of patients with muscular dystrophy.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a severe, recessive
X-linked form of muscular dystrophy, characterized by rapid
progression of muscle degeneration that eventually leads to
loss in ambulation, paralysis and death. The disorder is
caused by a mutation in the gene encoding dystrophin, an
important structural component of muscle tissues. The
absence of intact dystrophin results in destabilization of the
extracellular membrane–sarcolemma–cytoskeleton architec-
ture, making muscle ﬁbres susceptible to contraction-
associated mechanical stress and degeneration. Skeletal
muscles degenerate progressively and irreversibly and are
replaced by ﬁbrotic tissues (1). Several protocols have been
developed for cell-based therapies, especially using an mdx
mouse model, in which mouse dystrophin is defective due to
a single point mutation (2,3).
There is no known cure for DMD. However, use of stem cells
or myogenic progenitors holds signiﬁcant potential as an
effective and suitable treatment. Myoblasts represent the
natural ﬁrst choice in cell-based therapy for skeletal muscle
due to their intrinsic myogenic commitment. However, myo-
blasts recovered from muscular biopsies are poorly expandable
in vitro and rapidly undergo senescence (1). Cells with myo-
genic potential are present in many other tissues, and these
cells readily form skeletal muscle under favourable culture con-
ditions (4). Indeed, cell-based therapy for damaged muscle
tissue has already reached the clinical setting, with several
types of cell populations being exploited (5,6). Experimental
approaches to DMD using animal models have also been
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(7), synovial membrane (8) and menstrual blood (9).
In any cell-based therapy, donor cells are frequently
rejected by recipients when transplanted in an allogeneic com-
bination. Rejection is caused by a mismatch of the human leu-
kocyte antigen (HLA). There are a large number of different
alleles of each HLA, so a perfect match of all HLAs
between donor cells and host cells is extremely rare.
HLA-E, together with HLA-G and HLA-F, is a non-classical
major histocompatibility complex class I (MHC Ib) molecule
(10), which plays an important role in immunosuppression.
Among Ib molecules, HLA-E exhibits a restricted pattern of
expression in different cell types (11) and is a ligand of
CD94/NKG2 receptors (12,13). The interaction of HLA-E
with the inhibitory CD94/NKG2 receptor results in the inhi-
bition of natural killer (NK) cell- and cytotoxic T lymphocyte-
dependent lysis (12,14). Uteroplacental immune privilege
systems utilize this immunosuppression through production
of HLA-E, HLA-F and HLA-G in the uterus and the placenta.
In this study, we investigated the immunomodulating effect
of HLA (class Ib) in a xenogeneic combination, using
placenta-derived cells expressing HLA-E. Human placental
artery-derived endothelial (hPAE) cells conferred dystrophin
to myocytes of ‘immunocompetent’ mdx mice, a model of
DMD, doing so with extremely high efﬁciency.
RESULTS
Derivation of hPAE cells
We successfully cultured a large number of hPAE cells
obtained from placental arteries of ﬁve donors by the
explant culture method (Fig. 1A; see Materials and
Methods). hPAE cells with endothelium-like morphology
(Fig. 1B) adhered to dishes and were regarded as being popu-
lation doubling (PD) 0 at day 2. They continued to proliferate
until PD 17 at day 20 (Fig. 1C). Cell proliferative capacity was
assessed by calculating the total number of PDs (PD level or
accumulative PDs) using the formula log10(total number of
cells/starting number of cells)/log10 2. Flow cytometric analy-
sis revealed that hPAE cells were positive for CD29 (integrin
b1), CD31 (PECAM-1), CD44 (Pgp-1/ly24), CD59, CD73,
CD105 and CD166 (ALCAM) and negative for CD45,
CD106 (VCAM-1) and CD117 (c-kit) (Fig. 1D and E).
Almost all the cells were positive for the endothelial marker
CD31 (97.7%), implying that the cells were of endothelial
origin. Reverse transcriptase (RT)–polymerase chain reaction
(PCR) analysis revealed that hPAE cells expressed the endo-
thelial markers constitutively (Fig. 1F). Immunocytochemical
analysis also indicated that the hPAE cells were positive for
CD31 and von Willebrand factor (vWF) (Fig. 1G). We next
tested whether hPAE cells would form an ‘angiogenesis
network’ when plated on Matrigel. As shown in Figure 1H,
culture of hPAE cells on extracellular matrix resulted in vas-
cular tube formation within 6 h. hPAE cells with vascular
tube formation were immunocytochemically positive for vas-
cular endothelial growth factor (VEGF) (Supplementary
Material, Fig. S1).
Expression of HLA-E in hPAE cells
Since non-classical MHC is involved in immune privilege
(10,15), we investigated whether hPAE cells produce HLA-E
after exposure to cytokines (16). hPAE cells started to express
HLA-E after exposure to cytokines at the transcriptional level
(Fig.2A)andtheproteinlevel(Fig.2BandC).Immunostaining
showed that HLA-E was mainly localized in the cytoplasm
(Fig. 2B, right). Western blot analysis using anti-HLA-
E-speciﬁc monoclonal antibody revealed a single discrete
band at 42 kDa, consistent with the molecular weight of
HLA-E protein (Fig. 2C). Immunoprecipitation analysis of the
cell supernatant showed a single band at 37 kDa, consistent
with the molecular weight of soluble HLA-E (sHLA-E)
protein (Fig. 2D), implying that sHLA-E is secreted.
Myogenic induction of hPAE cells in vitro
We then investigated whether hPAE cells are capable of dif-
ferentiating into skeletal myocytes in vitro (Fig. 3). hPAE
cells started to exhibit multinucleated myotubes in culture
after induction (Fig. 3A). Immunocytochemistry indicated
that enhanced green ﬂuorescent protein (EGFP)-labelled mul-
tinucleated myotubes were positive for desmin (Fig. 3B) and
myosin heavy chain (Fig. 3C and D). Myogenesis of hPAE
cells was also analysed by RT–PCR with primers that can
amplify human myogenic genes, but not their mouse counter-
parts. hPAE cells constitutively expressed the myogenin gene
and started to express the desmin and MyHC-IIx/d genes after
induction (Fig. 3E). We also performed tartrate-resistant acid
phosphatase stain for osteoclasts, alkaline phosphatase stain
for osteoblasts and Oil red O stain for adipocytes on hPAE
cells at 21 days after the start of co-cultivation (Supplementary
Material, Fig. S2), but failed to detect positive reaction by
these stains.
Direct implantation of hPAE cells into immunocompetent
BALB/c mice
To further evaluate the in vivo response to hPAE cells, cells
were directly injected into the thigh muscles of immunocom-
petent BALB/c mice (17). For comparison, periosteal cells
with low expression of HLA-E were injected in the same
manner. Histopathological analysis revealed that the injection
of periosteal cells induced an immune response at the injected
site (Fig. 4A), but hPAE cells did not (Fig. 4B), suggesting
that hPAE cells fail to elicit pro-inﬂammatory responses in
immunocompetent mice. Immunohistochemical analysis,
using an antibody speciﬁc to human vimentin, revealed that
the hPAE cells extensively migrated between muscular ﬁbres
(Fig. 4B, lower panels). Immunoﬂuorescent analysis revealed
that CD45 and CD3 lymphocytes inﬁltrated near the (donor)
periosteal cells at 2 days after the injection into the Balb/c
muscle, and the number of lymphocytes increased at 2
weeks (Fig. 4C). In contrast, CD45- and CD3-positive cells
were not detected around the vimentin-positive hPAE cells
at 2 weeks. We also performed immunoﬂuorescent analysis
and western blot analysis to investigate the expression of
HLA-E in vivo. hPAE cells expressed HLA-E in the muscle
tissues (Fig. 4D and E). Moreover, HLA-E expression
236 Human Molecular Genetics, 2011, Vol. 20, No. 2Figure 1. In vitro characterization of hPAE cells. (A) Macroscopic views showing an explant culture method of hPAE cells. hPAE cells were dissected from
isolated placenta arterial vessels (indicated by arrowheads) in human placenta. (B) Photos showing morphology of hPAE cells by phase contrast microscopy at
primary stages at passage I (left panel: PD 0 and right panel: PD 3). (C) Proliferative capacity of hPAE cells. The number of cells was counted with ViCell
(Beckman Coulter) at each passage. The total number of PDs (PD level or accumulative PDs) was calculated, using the formula log10(total number of cells/
starting number of cells)/log10 2. (D) Flow cytometric proﬁles indicating expression of several cell surface markers on hPAE cells. (E) Scores of peak intensity,
compared with isotype controls. ‘++’: strongly positive (10 times and above that of the isotype control), ‘+’: weakly positive (,10 times and twice and above
that of the isotype control), ‘2’: negative (less than twice that of the isotype control). (F) RT–PCR analysis for endothelial marker expression in hPAE cells at
passage VI, IX and XX. The cells were cultured without any inductive stimuli. RNAs from HUVECs and H2O serve as positive (P) and negative (N) controls,
respectively. (G) Immunocytochemical analyses of CD31 and vWF in hPAE cells. (H) Phase contrast micrograph of in vitro endothelial network formation of
hPAE cells. hPAE cells were cultured on a basement membrane matrix gel. An ‘angiogenesis network’ was formed 6 h after cultivation began.
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leukin-4 (IL-4), which is essential for transplantation immu-
nity. IL-4 production reached a maximum level after 2
weeks at the injected site and then decreased (Supplementary
Material, Fig. S3).
ToinvestigatewhetherhPAEcellscangeneratemuscletissue
in vivo, hPAE cells were implanted directly into the right thigh
musclesofBALB/cmice,withphosphate-bufferedsaline(PBS)
beinginjectedatthecontralateralmusclesasacontrol.Immuno-
histochemicalanalysiswasperformedusingthehuman-speciﬁc
antibodyat3weeksafterinjection.Myotubesattheinjectedsite
expressed human dystrophin as a cluster. No positive reaction
wasdetectedinthemuscleofBALB/cmicewithoutcellimplan-
tation (PBS alone) (Fig. 4E and F; Supplementary Material,
Fig. S4). These results imply that dystrophin is transcribed
from the dystrophin gene of human donor cells after hPAE
cells differentiated into myotubes and fused to host myocytes
withoutimmuneresponse.Todeterminewhetherhumandystro-
phin expression in the donor cells is caused by fusion, immuno-
histochemistry with an antibody against human nuclei
(Ab-HuNucl) and 4′,6-diamidino-2-phenylindole (DAPI) stain
was performed. We examined almost all the 7 mm thick serial
histological sections parallel to the muscular bundle (cross-
section) of the muscular tissues by confocal microscopy and
found that myocytes had nuclei derived from both human and
murinecellsinthecross-section(Fig.4G),implyingthatdystro-
phin expression is attributed to fusion between murine host
myocytes and human donor cells.
Inhibition of HLA-E by small interfering RNA (siRNA)
To investigate the involvement of HLA-E in immunosuppres-
sion, we suppressed HLA-E expression by siRNA in hPAE
cells. A signiﬁcant decrease in HLA-E mRNA was observed
Figure 2. HLA-E mRNA and protein in hPAE cells upon treatment with tumor
necrosis factor a (TNFa) and interferon g (IFNg). (A) RT–PCR showing a
time-course of HLA-E expression in response to TNFa and IFNg. 18S
RNA was used as a loading control. M ¼ size markers and N ¼ a negative
control in PCR with H2O. (B) Immunocytochemistry of HLA-E localization.
The cells were incubated for 24 h with a combination of TNFa and IFNg at
the indicated concentrations (right). Left panel ¼ untreated control. (C)
Western blot analysis of cell lysates showing levels of HLA-E at 24 h after
treatment with TNFa and IFNg. Combination of two reagents induced more
HLA-E at the protein level. Actin was used as a loading control. (D) Immuno-
precipitation analysis of culture supernatants showing a soluble form of
HLA-E (sHLA-E) with exposure to TNFa and IFNg. sHLA-E level was deter-
mined by each signal intensity (mean+SE). n ¼ 3, ∗P , 0.05.
Figure 3. Myogenic differentiation of hPAE cells under cell culture con-
ditions. (A) Photos showing myogenic differentiation of hPAE cells detected
by phase contrast microscopy (left) and by ﬂuorescent microscopy (right) in an
identical area. EGFP-labelled hPAE cells co-cultured with neonatal murine
thymocytes for 21 days. (B and C) Immunocytochemistry of hPAE cells
expressing myogenic markers, desmin (B) and skeletal myosin heavy chain
(C, MY32). (D) Quantitative analysis of MY32-positive hPAE cells. MY32-
and EGFP-double positive cells (no. of MY32+ EGFP+ cells) were
counted in 35 mm dishes 3 weeks after induction (mean+SE). n ¼ 3, ∗P ,
0.05. (E) RT–PCR showing myocyte-speciﬁc genes were expressed along
with myogenic differentiation. RT–PCR analysis with PCR primers that
amplify only human mRNAs of Myf5, myogenin, desmin and MyHC-IIx/d,
but not murine mRNAs. RNAs from human muscle and H2O served as posi-
tive (P) and negative (N) controls, respectively.
238 Human Molecular Genetics, 2011, Vol. 20, No. 2in the cells transfected with HLA-E siRNA (siHLA-E) when
compared with control cells (Fig. 5A). In the same set of
experiments, HLA-E protein decreased signiﬁcantly in
siHLA-E-transfected cells when compared with control cells
(Fig. 5B). To investigate the involvement of HLA-E in
in vivo immune response, after pre-treatment with 20 mM
siHLA-E for 48 h, hPAE cells were injected into the thigh
muscles of immunocompetent BALB/c mice, with hPAE
cells treated with control siRNA being injected into the con-
tralateral muscles as a control (Fig. 5C–F). Histopathological
analysis revealed that injection of siHLA-E-treated hPAE cells
elicited an immune response, as revealed by inﬁltration of
CD3- and CD45-positive lymphocytes in immunocompetent
BALB/c mice 7 days after injection, whereas injection of
Figure 4. Implantation of hPAE cells into the thigh muscle of BALB/c mice. (A) Human periosteal cells (2 × 10
7 cells) were injected directly into the thigh
muscles of BALB/c mice. Immunohistochemical analysis was performed on the muscle section using an antibody against vimentin. Upper panels: 2 days after
injection and lower panels: 2 weeks after injection. (B) hPAE cells (2 × 10
7 cells) were injected directly into the thigh muscles of BALB/c mice. Upper panels:
immunohistochemistry against vimentin. Lower panels: immunoﬂuorescent analysis. DAPI (blue), vimentin (green), laminin (red) and MERGE (from left to
right). (C) Immunohistochemical analysis of the thigh muscle sections at 2 days or 2 weeks after injection of human periosteal cells (hPeriosteal) and at 2
weeks after injection of hPAE cells, using antibodies against vimentin (upper panels: red and lower panels: green), leukocyte marker CD45 (green) andT
cell marker CD3 (red). (D) Immunoﬂuorescent analysis using an antibody against HLA-E (red) and human laminin (green) on the thigh muscle sections at 2
weeks after injection of hPAE cells. (E) Western blot analysis of muscle lysates showing levels of HLA-E, dystrophin and laminin. BALB/c mice were implanted
with PBS or hPAE cells at the indicated weeks. The level of actin protein was used as a loading control. (F) Immunoﬂuorescent analysis using an antibody
against human dystrophin (green) on thigh muscle sections 3 weeks after direct injection of hPAE cells (middle and lower panels). PBS was injected into con-
tralateral muscles as a control (upper panels). Dystrophin is totally absent in PBS-injected muscles (upper panels), whereas clusters of muscle ﬁbres display
peripheral localization of the dystrophin protein in mice injected with hPAE cells (middle and lower panels). Dystrophin (green), DAPI (blue) and MERGE
(from left to right). (G) Immunoﬂuorescent analysis using antibodies against laminin (green), human nuclei (HuNucl, red, arrows) and DAPI staining (blue,
arrowheads) on thigh muscle sections 3 weeks after injection of hPAE cells.
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This suggests that HLA-E is necessary for inhibition of an
immune reaction in vivo. We then investigated whether lysis
of hPAE cells by primed lymphocytes is mediated by
HLA-E. hPAE cells treated with either siHLA-E or control
siRNA were co-cultured with spleen-derived lymphocytes,
and induction of xenoreactive lysis was quantiﬁed (Fig. 5G
and H). siHLA-E-treated hPAE cells were lysed by primed
lymphocytes, whereas control siRNA-treated hPAE cells
were not, indicating that HLA-E is also necessary for inhi-
bition of the immune response in vitro.
Conferral of human dystrophin by cell implantation
in the mdx mouse
To investigate whether hPAE cells can confer human dystro-
phin to myocytes, untreated EGFP-labelled cells were
implanted directly into the thigh muscles of mdx mice
(Fig. 6A). PBS was injected into the contralateral muscles as
a control (Fig. 6B). At 3 weeks after implantation, human dys-
trophin was detected in EGFP-positive myotubes as a cluster
at 18.2% (Fig. 6C). Expression of dystrophin was not caused
by reversion to the normal phenotype of dystrophied myocytes
Figure 5. Functional effect of HLA-E siRNA on immunosuppression. (A) Inhibition of HLA-E mRNA by siRNA. hPAE cells (1 × 10
4) grown on 6-well plates
were transfected with either control siRNA or HLA-E-speciﬁc siRNA (20 mM) for 48 h. HLA-E mRNA levels were quantiﬁed using RT–PCR, normalized to
b-actin (mean+SE). n ¼ 3, ∗∗P , 0.01. (B) Inhibition of HLA-E protein by siRNA. Whole-cell protein extracts were analysed by SDS–PAGE immunoblotting
with antibodies to HLA-E and actin. (C–F) siHLA-E-treated hPAE cells and control siRNA-treated hPAE cells were injected into the right and left thigh muscle
of BALB/c mice, respectively. Mice were sacriﬁced 7 days after injection. (C) Injected sites are indicated by arrows (left: control siRNA and right:
HLA-E-speciﬁc siRNA). (D) Microscopic view (HE stain and immunohistochemistry) of thigh muscles implanted with siHLA-E-treated (upper panels) or
control siRNA-treated (lower panels) hPAE cells. (E and F) Immunohistochemical analysis of thigh muscle sections, after injection of siHLA-E-treated or
control siRNA-treated hPAE cells and staining with antibodies against vimentin (E: red and F: green), leukocyte marker CD45 (E: green) and T cell marker
CD3 (F: red). (G) Induction of xenoreactive lysis with spleen-derived lymphocytes. siHLA-E-treated hPAE cells or control siRNA-treated hPAE cells were
co-cultured with spleen-derived lymphocytes and immunocytochemically stained for human vimentin. (G) Upper left: hPAE cells, upper right: siHLA-E-treated
hPAE cells without any co-cultivation, lower left: control siRNA-treated hPAE cells co-cultured with primed lymphocytes, lower right: siHLA-E-treated hPAE
cells co-cultured with primed lymphocytes. (H) Survival of hPAE cells after xenoreactive analysis. Vimentin-positive cells (no. of vimentin+ cells/mm
2) sig-
niﬁcantly decreased in siHLA-E-treated cells when compared with control siRNA-treated cells 3 days after co-incubation with primed lymphocytes. ∗P , 0.01,
NS ¼ not signiﬁcant.
240 Human Molecular Genetics, 2011, Vol. 20, No. 2in the mdx mice because the antibody used in this study is
speciﬁc to humans. These results suggest that human dystro-
phin is transcribed from the dystrophin gene of human donor
cells.
DISCUSSION
DMD is a devastating X-chromosome-linked muscle disease
characterized by progressive muscle weakness attributable to
a lack of dystrophin expression at the sarcolemma of muscle
ﬁbres (18). There are currently no effective therapeutic
approaches for muscular dystrophy. hPAE cells have a high
replicative ability, similar to progenitors or stem cells that
display a long-term self-renewal capacity, and had a much
higher growth rate in our experimental conditions than
marrow-derived stromal cells (19). Immunosuppressive
hPAE cells with a direct myogenic potential thus offer signiﬁ-
cant potential for novel, effective and sustainable cell-based
therapy, including when being used in an allogeneic manner.
The function of HLA-E has been fully elucidated through its
interaction with CD94-NKG2 receptors expressed on NK
cells and a subset of T cells (12,13). In vitro studies using
human cells provided evidence of HLA-E involvement in
negative signalling to immune responses (20). Qa-1 (homolo-
gous to HLA-E in mice)-deﬁcient mice have defects in immu-
noregulation mediated by T cells (21). Survival of donor cells
in an immunocompetent mouse is attributed, at least partially,
to HLA-E-dependent immunosuppression, because knock-
down experiments of HLA-E clearly indicate involvement of
HLA-E in cell-mediated lysis of hPAE cells (Fig. 5). HLA-E
is a protective response of hPAE cells to injury and plays an
important role in immunosuppression, irrespective of being
either the membrane-bound or soluble form.
It is noteworthy that hPAE cells, as well as other placenta-
derived cells, are obtained by a simple, safe and painless pro-
cedure, and a large number of hPAE cells can easily be har-
vested from placental arteries. In this study, we manually
separated chorionic large arteries from the chorionic plate
that entirely covers the foetal surface of the placenta, which
is, in turn, covered by the aminion (Fig. 1A). hPAE cells pro-
liferate over at least PD 17 for .20 days and stop dividing
before PD 22. The predicted number of CD31-positive
hPAE cells from one placenta of an average size (500 g)
would be 1 × 10
7 (before ex vivo ampliﬁcation), possibly
reaching 1 × 10
12 after cultivation. This may cover
30 000 cm
3 of muscular tissues in cell-based therapy (5).
Cells converted into myotubes in vitro at a high frequency
after induction, giving rise to large numbers of myoﬁbres
expressing human dystrophin when transplanted into BALB/
c and mdx mice, thus fulﬁlling all the criteria required for a
successful allogeneic cell therapy for muscular dystrophy.
Compared with previously reported experiments, including
from our laboratory (9), the frequency of myotubes with
human dystrophin after cell implantation was extremely
high. In addition to in vivo myogenesis, in vitro myogenesis
was induced. Myogenin, a helix–loop–helix transcription
factor, determines muscle cell fate and accelerates cell
fusion, and is constitutively expressed in hPAE cells, implying
either that these cells have myogenic potential or that these
cells are myogenic progenitors, although their origin is endo-
thelial from the viewpoint of isolation procedure and cell
surface markers. Myogenesis may also be promoted by cyto-
kines such as VEGF (22) as well as transcription factors. Fur-
thermore, in cases of cell-based therapy, the so-called ‘space’
is necessary for survival of implanted donor cells. Irradiation
has been used for the generation of space in cases of bone
marrow transplantation. Toxin, to induce muscle injury and
pathophysiological ischaemia of muscular tissues, can also
generate space in muscle (23). BALB/c and mdx mice were
used in this study, and almost identical results were obtained
from both mice types, although BALB/c mice theoretically
do not have any muscular injury. High frequency of human
Figure 6. Conferral of dystrophin to mdx myocytes by hPAE cells.
(A) EGFP-labelled hPAE cells were injected into the thigh muscle of mdx
mice. Immunohistochemical analysis revealed the incorporation of implanted
cells into newly formed EGFP-positive myoﬁbres (green), which expressed
human dystrophin (red) 3 weeks after implantation. (B) PBS was injected
into contralateral muscles as a control. (C) Quantitative analysis of human
dystrophin-positive myotubes. The percentage of human EGFP- and
dystrophin-positive myoﬁbre areas (% double positive area) was calculated
3 weeks after injection of cells or PBS (mean+SE). n ¼ 3, ∗P ¼ 0.05.
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the generation of space by the immune response after cell
implantation in a xenogeneic combination. hPAE cells
produce HLA-E after immunoreaction by production of immu-
nocytokines such as IL-4 (Supplementary Material, Fig. S1),
followed by induction of immunosuppression through
HLA-E. This immune reaction after cell implantation possibly
generates space to enable survival of implanted cells. This
possibility is rather favourable because any future cell-based
therapy for DMD patients will be employed in an allogeneic
combination. In contrast, experimental approaches have been
tested in a syngeneic combination, in immunodeﬁcient mice
or via use of immunosuppressive drugs. Clinical trials in
humans, use an allogeneic combination (5,6), are in no way
inferior compared with experimentation with the murine
model systems. This study may explain the high frequency
of donor cell survival at the implanted sites observed in clini-
cal trials.
Induction of immunosuppression via HLA-E from hPAE
cells observed in this study directly leads to the possibility
of clinical, allogeneic cell-based therapy. Mesenchymal stem
cells (MSCs) or mesenchymal progenitors, isolated from
bone marrow as an adherent ﬁbroblast-like population (24),
have already been identiﬁed in many tissues, including
umbilical-cord blood (25), the placenta (26), fat and amniotic
ﬂuid (27). They have been used for cell-based therapy because
of their self-renewal capacity and their ability to form bone,
fat, cartilage, muscle, cardiocytes and neurons (28,29). The
isolation of tissue-speciﬁc stem cells for expansion in vitro
and transplantation back into the patient in an allogeneic
manner is an ideal strategy, from the viewpoint of industry-
based, sustainable supply of large quantities of affordable,
quality-controlled cells. Using autologous MSCs to restructure
damaged tissues has had some clinical success (30). In most
cases of degenerative and genetic diseases, it is unlikely that
enough unaffected stem cells will be isolated or available in
sufﬁcient quantity, necessitating the use of stem cells from
suitable, cost-effective allogeneic sources such as placenta.
MATERIALS AND METHODS
Cultivation of hPAE cells
Human placentas were collected, after delivery, with informed
consent. Ethical approval was granted by the Institutional
Review Board. To isolate arterial endothelium, we used the
explant culture method, in which the cells were outgrown
from pieces of placenta arterial vessels (Fig. 1A). Brieﬂy,
arterial vessels were separated from arteries in the chorionic
plate and chopped into  5m m
3 pieces. The pieces were
washed in endothelial basal medium (EBM)-2 (Cambrex,
Walkersville, MD, USA) and cultured in endothelial growth
medium-2 MV (EGM-2MV; Cambrex), which consisted of
EBM-2, 5% foetal bovine serum (FBS) and supplemental
growth factors including VEGF, basic ﬁbroblast growth
factor, epidermal growth factor and insulin-like growth
factor. Arterial vessels attached to the substratum of culture
dishes (BD Falcon; Becton Dickinson and Company, San
Jose, CA, USA), and cells migrate out from the surface of
tissues after 20 days of incubation at 378Ci n5 %C O 2. The
cells were harvested with PBS, with 0.1% trypsin and
0.25 mM EDTA, and were re-seeded at a density of 3 × 10
5
cells in a 10 cm diameter dish. Conﬂuent monolayers of
cells were further subcultured. The culture medium was
replaced every 3–4 days.
In vitro lentivirus-mediated gene (EGFP) transfer into
hPAE cells
Infection of cultured hPAE cells with lentivirus (having a
CMV promoter-regulated EGFP reporter plasmid) resulted in
high levels of EGFP expression in all cells. EGFP expression
was analysed by ﬂow cytometry (31).
Flow cytometric analysis
Flow cytometric analysis was performed as described pre-
viously (9). Cells were incubated with primary antibodies or
isotype-matched control antibodies followed by immunoﬂuor-
escent secondary antibody staining. Cells were analysed on an
EPICS ALTRA analyser (Beckman Coulter, Fullerton, CA,
USA). Antibodies against human CD29, CD31, CD44,
CD45, CD59, CD73, CD105, CD106, CD117, CD166 and
VEGER (FIk-1) were purchased from Beckman Coulter,
Immunotech (Marseille, France), Cytotech (Hellebaek,
Denmark) and BD Biosciences Pharmingen (San Diego, CA,
USA).
Myogenic differentiation of hPAE cells
A cell suspension was prepared from neonatal murine thymi
using frosted slide glasses (MUTO-Glass, Japan). The thymo-
cyte suspension was then washed once in PBS with 2% FBS
and ﬁltered through a 100 mm nylon mesh. After centrifu-
gation at 1000 rpm for 5 min, the cell pellet was re-suspended
in 10% FBS/Dulbecco’s modiﬁed Eagle’s medium. Floating
thymocytes were collected and re-plated at 1 × 10
6/cm
2. The
next day, hPAE cells were harvested with 0.25% trypsin and
1m M EDTA and overlaid onto the cultured neonatal thymo-
cytes at 1 × 10
4/cm
2. The culture medium was replaced
every 2 days with fresh EGM-2 MV.
RT–PCR analysis
Total RNAs (2 mg) were reverse-transcribed with oligo (dT),
as described previously (9), and RT–PCR was carried out
with primer sets speciﬁc for human Myf5, myogenin,
desmin, myosin heavy chain-IIx/d (MyHC-IIx/d) (primer
sequences are shown in Supplementary Material, Table S1).
Human muscle RNAs and H2O served as positive (P) and
negative (N) controls, respectively. The 18S PCR primers
were used as a positive control for both human and murine
cDNAs. The HLA-E primers (F: CCACCATGGTAGATG
GAACCC and R: GCTTTACAAGCTGTCAGACTC) used
were the same as those described previously (16). The
primer sequences of endothelial cell markers are listed in Sup-
plementary Material, Table S1. Human umbilical vein endo-
thelial cell (HUVEC) RNAs and H2O served as positive (P)
and negative (N) controls, respectively. Glyceraldehyde phos-
phate dehydrogenase was also used as a positive control.
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total RNAs were isolated from HLA-E-speciﬁc siRNA or
control siRNA-transfected hPAE cells using an RNeasy
mini-kit (Qiagen, Chatsworth, CA, USA) and were reverse-
transcribed by TaKaRa recombinant Taq (Takara Bio Inc.,
Japan). Real-time PCR was carried out with an ABI PRISM
7000 Sequence Detection System. The 25 ml reaction
mixture contained 12.5 ml of SYBR Green PCR Master Mix
(TOYOBO, Japan), 10 ng of cDNA template and a primer
set for HLA-E, F: CGGCTACTACAATCAGAGCGA and
R: CACGCATGTGTCTTCCAGG or for b-action, F: CATG-
TACGTTGCTATCCAGGC and R: CTCCTTAATGTCACG-
CACGAT. The relative quantiﬁcation of the transcripts was
analysed using the comparative threshold cycle method sup-
plied by the manufacturer.
Immunohistochemical and immunocytochemical analyses
For immunohistochemical analysis (19), the skeletal muscle
tissue section slides (parafﬁn-embedded) were incubated
with anti-vimentin monoclonal antibody (clone: V9, Dakocy-
tomation, Glostrup, Denmark) for 1 h at room temperature,
followed by horseradish peroxidase (HRP)-conjugated second-
ary antibody. Staining was detected by diaminobenzidine and
H2O2. Slides were counterstained with haematoxylin. For the
immunoﬂuorescence, antibodies against human dystrophin
(NCL-DYS3, Novocastra, Newcastle upon Tyne, UK), GFP
(Catalogue no. 632377, Clontech, Mountain View, CA,
USA), human nuclei (Catalogue no. MAB1281, Chemicon,
Temecula, CA, USA), HLA-E (clone 4D12, MBL, Japan),
vimentin, CD45 (leukocyte common antigen) (clone 30-F11,
Invitrogen, Camarillo, CA, USA), CD3 (Catalogue no.
sc-1127, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and laminin (Mob 202, clone 4C7, DBS, CA, USA; 4H8-2,
ab11576, Abcam plc, Cambridge, UK) were used as ﬁrst anti-
bodies, followed by Alexa-Fluor-conjugated secondary anti-
bodies (Molecular Probes, Eugene, OR, USA).
Immunocytochemical analysis was performed as described
previously (19). The antibodies against CD31 (Catalogue no.
SCR023, Part no. 2003788, Chemicon), vWF (Catalogue no.
SCR023, Part no. 2003787, Chemicon), VEGF (clone
EP1176Y, Abcam plc), desmin (clone D9, Catalogue no.
010031, BioScience Products, Emmenbruecke, Switzerland),
skeletal myosin (clone MY-32, Sigma-Aldrich, Inc., St
Louis, MO, USA), GFP and vimentin were used as ﬁrst anti-
bodies and Alexa-Fluor-conjugated goat anti-mouse (rabbit)
IgG and HRP-conjugated rabbit anti-mouse IgG were used
as second antibodies.
Western blotting and immunoprecipitation
Western blot analysis was performed as described previously
(19). Blots were incubated with primary antibodies for
HLA-E (clone MEM-E/02, Serotec, Oxford, UK), laminin
(Mob 202, clone 4C7, DBS) or dystrophin (NCL-DYS3,
Novocastra) for 1–2 h at room temperature. After washing,
blots were incubated with an HRP-conjugated secondary anti-
body (0.04 mg/ml) for 30 min. The blots were developed with
enhanced chemiluminescence substrate, according to the
manufacturer’s protocol.
For immunoprecipitation, the supernatants of hPAE cell
were incubated with HLA-E antibody (1–2 mg for each
sample) for 1 h, followed by incubation with 20 mlo f
protein A/G plus agarose overnight at 48C. The supernatants
were removed by centrifugation, and the pellets were boiled
in 2× sample buffer for 4 min. The products were then
applied to sodium dodecyl sulphate (SDS)–polyacrylamide
gel electrophoresis (PAGE).
siRNA study
The HLA-E siRNA pool (HLA-E-HSS104836, HLA-E-
HSS104837 and HLA-E-HSS104838) was purchased from
Invitrogen (Carlsbad, CA, USA) and transfected into hPAE
cells using Lipofectamine
TM RNAiMAX (Invitrogen). Cells
were harvested 48 h after transfection and analysed by real-time
PCR and western blot.
Xenoreactive immune response
Lymphocytes from BALB/c mouse spleen were isolated by
Ficoll/Histopaque density gradient centrifugation. hPAE cells
were transfected with either control siRNA or HLA-E-speciﬁc
siRNA (20 mM) for 48 h. The two cell populations were then
co-cultured for 3 days in 2 ml of RPMI supplemented with
10% FBS and 10 U/ml IL-2 (Catalogue no. 212-12, Peprotech
Inc., Rocky Hill, NJ, USA). Induction of xenoreactive lysis in
the spleen-derived lymphocytes was quantiﬁed by immuno-
staining with a human-vimentin-speciﬁc antibody.
In vivo cell implantation
hPAE cells were implanted into the thigh muscle of 4- to
6-week-old BALB/c (Sankyo Labo Service Corporation,
Hamamatsu, Japan) or mdx (C57BL/10ScSn-Dmdmdx/J, Jax
Labs, Bar Harbor, ME, USA) mice. For comparison, human
periosteal cells were used. The cells (2 × 10
7) were suspended
in PBS in a total volume of 100 ml and injected directly into
the thigh muscles. The mice were examined 2 days or 1, 2,
3, 4 and 6 weeks after injection by immunohistochemistry
with antibodies against HLA-E, vimentin, laminin and dystro-
phin. The antibodies for vimentin and dystrophin
(NCL-DYS3) are human tissue speciﬁc; therefore, they do
not react with murine tissues or murine tissue-derived pro-
teins. In addition, siHLA-E (20 mM)-treated or control siRNA-
treated hPAE cells were injected directly into the thigh muscle
of BALB/c mice.
Statistical analysis
Statistical analysis was performed using the Student’s t-test.
A 95% conﬁdence limit was taken as signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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